CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing, such as cystic fibrosis (CF), today announced two abstracts will be presented during the flash poster presentation sessions at the 13th Annual European Cystic Fibrosis Society Basic Science Conference. The meeting will take place March 30-April 2 at Green Park Resort near Pisa, Italy. The company will hold a conference call and webcast on March 30, 2016 at 4:00 p.m. ET to discuss the data being presented at the conference and the company’s outlook for 2016.
Following is a schedule of the company’s flash poster presentations and conference call:
Thursday, March 31
Time: 2:30-3:30 p.m. CEST
Title: Characterization of CFTR amplifiers, mutation-agnostic modulators that increase protein levels and complement other CF therapeutic modalities
Friday, April 1
Time: 6:30-7:30 p.m. CEST
Title: A novel corrector for F508del-CFTR that complements existing CFTR modulators in vitro
Conference Call and Webcast
Wednesday, March 30
Time: 4:00 p.m. ET
The conference call can be accessed by dialing 1-877-626-4740 (toll-free domestic) or 1-281-973-6278 (international) and referring to conference ID 78792593. A live webcast and accompanying slide presentation will be available on the Event Calendar page in the Investors & Media section of the company’s website, www.proteostasis.com. A replay of the webcast will be available on the company’s website shortly after the conclusion of the conference call.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery of groundbreaking therapies to treat diseases caused by dysfunctional protein processing, such as cystic fibrosis (CF). Headquartered in Cambridge, MA, the Proteostasis Therapeutics team focuses on identifying therapies that modulate the proteostasis imbalance in cells and restore protein function. Proteostasis Therapeutics is currently enrolling eligible adults with CF to participate in its Phase 1 clinical trials of PTI-428, a unique CFTR modulator, called a CFTR amplifier, that when used in combination with existing treatments and therapies has shown a consistent positive effect on CFTR protein activity in pre-clinical studies. In addition to its multiple programs in cystic fibrosis, Proteostasis Therapeutics has formed collaborations with Biogen to research and identify therapeutic candidates for neurodegenerative disease and with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. For more information visit www.proteostasis.com.
Dan Budwick, Pure Communications, Inc.
Luke Heagle, Pure Communications, Inc.
Source:Proteostasis Therapeutics, Inc